Scinai Immunotherapeutics Ltd. (SCNI) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2025
Loading P/E history...
SCNI Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Scinai Immunotherapeutics Ltd. (SCNI) trades at a price-to-earnings ratio of -0.2x, with a stock price of $0.54 and trailing twelve-month earnings per share of $2.57.
The current P/E is 124% below its 5-year average of 0.6x. Over the past five years, SCNI's P/E has ranged from a low of 0.0x to a high of 1.9x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, SCNI trades at a 101% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SCNI trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SCNI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SCNI P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 3.6Lowest | - | +307%Best | |
| $178M | 10.6 | - | +150% | |
| $8B | 25.5 | 1.11Best | -25% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SCNI Historical P/E Data (2021–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $2.28 | $1.20 | 1.9x | +200% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $2.78 | $26461.60 | 0.0x | -100% |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $287.00 | $134920.00 | 0.0x | -100% |
Average P/E for displayed period: 0.6x
See SCNI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SCNI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SCNI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSCNI — Frequently Asked Questions
Quick answers to the most common questions about buying SCNI stock.
Is SCNI stock overvalued or undervalued?
SCNI trades at -0.2x P/E, below its 5-year average of 0.6x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SCNI's valuation compare to peers?
Scinai Immunotherapeutics Ltd. P/E of -0.2x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is SCNI's PEG ratio?
SCNI PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2025.